The treatment of multiple sclerosis is being revolutionized by the new drugs that no longer have to be taken in the hospital, with long infusions replaced by tablets, and which must be taken only for a few weeks, with an efficacy that lasts for years. This is the case of a relatively new molecule, Cladribine tablets: new data at two years of follow-up show how it has improved the quality of life in patients with highly active MRI. Furthermore, a two-year follow-up study showed that the action on the reduction of lesions on MRI with cladribine tablets was maintained from the second month of treatment up to two years. These are the results presented by the pharmaceutical company Merck at the 38th Ectrims congress, the most important scientific event dedicated to research on multiple sclerosis, taking place in Amsterdam. In the final analysis of the Phase IV ‘Clarify-Ms’ study, the company explains, statistically significant improvements in physical and mental health were observed, as measured by the Multiple Sclerosis Quality of Life-54 questionnaire. new MRI data from a phase IV study, ‘Magnify-Ms’, which showed drug onset of action from the second month of treatment, with a sustained reduction in the number of MRI lesions up to two years in people with highly active relapsing multiple sclerosis treated with cladribine tablets. The percentage of lesion-free patients increased from 47% to 86.2% at the end of the study (18-24 months). Over the two years, the benefit / risk profile of cladribine tablets remained unchanged and consistent with that observed during the clinical trial. In total, Merck presents 39 studies at Ectrims.